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Key Points
• The NIH joint/fascia
score and total P-ROM
score should be used
for assessing therapeu-
tic response in joint/
fascia chronic GVHD.
• A change from 0 to 1
on the NIH joint/fascia
score should not be
considered as
worsening.
Implementation of the 2014 National Institutes of Health (NIH) response algorithm for joint/
fascia graft-versus-host disease (GVHD) has identified real-world limits to its application. To
refine the 2014 NIH response algorithm, we analyzed multicenter prospective observational
data from the Chronic GVHD Consortium. The training cohort included 209 patients and the
replication cohort included 191 patients with joint/fascia involvement during their course of
chronic GVHD. Linear mixed models with random patient effect were used to evaluate
correlations between response categories and clinician- or patient-perceived changes in
joint status as an anchor of response. Analysis of the training cohort showed that a 2-point
change in total photographic range of motion (P-ROM) score was clinically meaningful. The
results also suggested that a change from 0 to 1 on the NIH joint/fascia score should not be
considered as worsening and suggested that both the NIH joint/fascia score and total P-ROM
score, but not individual P-ROM scores, should be used for response assessment. On the basis of
these results, we developed an evidence-based refined algorithm, the utility of which was
examined in an independent replication cohort. Using the refined algorithm,;40%of responses
were reclassified, largely mitigating most divergent responses among individual joints and
changes from 0 to 1 on the NIH joint/fascia score. The refined algorithm showed robust point
estimates and tighter 95% confidence intervals associated with clinician- or patient-perceived
changes, compared with the 2014 NIH algorithm. The refined algorithm provides a superior,
evidence-based method for measuring therapeutic response in joint/fascia chronic GVHD.
Introduction
Chronic graft-versus-host disease (GVHD) is a systemic immunological complication that occurs in
approximately half of allogeneic hematopoietic cell transplantation survivors and is the leading cause of
late morbidity and mortality.1 Joint/fascia involvement occurs in 3% to 24% of patients who have chronic
GVHD.2-6 Joint/fascia manifestations include joint stiffness, arm or leg tightness, edema, restricted joint
range of motion and arthralgia arising from inflammation, and fibrosis of superficial or deep tissues
(subcutaneous sclerosis/fasciitis).7 Isolated deep involvement may occur while the overlying skin
remains freely mobile.8
The development of National Institutes of Health (NIH) response criteria for chronic GVHD therapy
through 2 consensus conferences9,10 led to the first regulatory approval of an agent for the treatment of
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this devastating complication.11 Currently, numerous new thera-
peutic targets and agents are being evaluated in prospective
clinical trials, and further refinement of existing response scales is
imperative for better drug development and benefit for patients.12
Therapeutic response in chronic GVHD with joint/fascia in-
volvement needs to be assessed reliably, simply, and in a clinically
meaningful way. The 2014 NIH response criteria paper defined
joint/fascia improvement as a decrease in NIH joint/fascia score
by at least 1 point or an increase in photographic range of motion
(P-ROM) score by at least 1 point at any site, whereas progression
was defined as an increase in NIH joint/fascia score by at least 1
point, including a change from 0 to 1, or decrease in P-ROM score
by at least 1 point at any site10; however, evidence is lacking on
the use of a single-site P-ROM score for assessing response. In fact,
a prior study demonstrated the utility of a change of at least 1 point in
total P-ROM score, derived from summing all joint scores.13
Several problems and contradictions have arisen in the implemen-
tation of the 2014 recommendation in clinical practice. First,
divergent changes in individual joints (eg, improvement in 1 joint but
worsening in another on individual P-ROM scores) are considered
overall progression according to the 2014 NIH algorithm. The
appropriateness of this recommendation had not been formally
examined. Second, a worsening of $1 point on the 4-point NIH
joint/fascia score (range, 0-3) is considered progression according
to the 2014 NIH organ scoring algorithm, but a change from 0 to 1
is not considered progression in most other sites, because this
often reflects mild, nonspecific, intermittent, self-limited symptoms
or signs that do not warrant a change of therapy.10 This exception
currently does not apply to the joint/fascia score based on
consensus opinion,10 but evidence is not available to support this
definition. Lastly, discrepant responses can occur between NIH
joint/fascia score and P-ROM score (eg, NIH joint/fascia score
worsens but P-ROM score improves), but there is no evidence-
based guidance on adjudicating those cases as overall improve-
ment, stability, or worsening.
We previously examined appropriate scales for assessing thera-
peutic response in joint/fascia GVHD and reported that the use of
both NIH joint/fascia score and total P-ROM score appropriately
captured changes in joint/fascia GVHD.13 Specifically, NIH joint/
fascia score better captured improvement, whereas total P-ROM
score better captured worsening.13 The present study extended
our previous analysis to evaluate the performance of the 2014 NIH
response algorithm for joint/fascia GVHD, using prospectively
collected multicenter observational data of patients with chronic
GVHD.14,15
Table 1. Characteristics of patients who had joint/fascia involvement
during their course of chronic GVHD
Characteristic Training Replication P
Total, n 209 191




Incident 114 (55) 59 (31)
Prevalent 95 (45) 132 (69)




Male 119 (57) 122 (64)
Female 90 (43) 69 (36)
Patient race .91
White 189 (90) 170 (89)
Nonwhite 17 (8) 18 (9)
Unknown 3 (1) 3 (2)
Stem cell source .14
Bone marrow 12 (6) 8 (4)
Mobilized blood cells 185 (89) 179 (94)
Cord blood 12 (6) 4 (2)
Female donor to male recipient 57 (27) 58 (30) .48
HLA and donor type .06
Matched related 101 (48) 70 (37)
Matched unrelated 85 (41) 94 (49)
Mismatched 23 (11) 27 (14)
Conditioning regimen .74
Myeloablative 106 (51) 89 (47)
Nonmyeloablative/reduced
intensity
101 (48) 100 (52)
Unknown 2 (1) 2 (1)
Involved site at enrollment
Skin 138 (66) 157 (82) ,.001
Eye 108 (52) 114 (60) .11
Mouth 112 (54) 106 (56) .76
Liver 34 (16) 18 (10) .05
Gastrointestinal tract 63 (30) 54 (28) .74
Joint/fascia 113 (54) 155 (81) ,.001
Lung 57 (27) 76 (40) .01
Genital tract* 20 (11) 27 (24) .005
NIH global score at enrollment ,.001
Mild 23 (11) 14 (7)
Moderate 131 (63) 72 (38)
Severe 55 (26) 105 (55)
Table 1. (continued)
Characteristic Training Replication P
P-ROM score in all visits,
mean 6 SD (half SD)
Shoulder 6.62 6 0.74 (0.37) 6.40 6 0.89 (0.45) ,.001
Elbow 6.69 6 0.72 (0.36) 6.52 6 0.83 (0.41) ,.001
Wrist 6.26 6 1.17 (0.59) 5.93 6 1.39 (0.70) ,.001
Ankle 3.59 6 0.57 (0.29) 3.49 6 0.69 (0.34) .04
Total score 23.2 6 2.34 (1.17) 22.4 6 2.97 (1.49) ,.001
Values are n (%) unless otherwise indicated.
SD, standard deviation.
*Among patients for whom the question was answered (186 in training, 114 in
replication).
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Patients and methods
Study cohort
Adult patients who were at least 18 years of age with systemically
treated chronic GVHD were enrolled for a prospective, multicenter,
longitudinal, observational study by theChronicGVHDConsortium.14,15
The consortium collected 2 independent cohorts of patients. The
first cohort included 488 patients with 1578 visits who were
enrolled from 2007 to 2012, and the second cohort included 357
patients with 1195 visits who were enrolled from 2013 to 2017.
Patients with recurrent disease or anticipated survival ,6 months
were not enrolled. Diagnosis and assessment of chronic GVHD
were made according to the 2005 NIH consensus criteria7 in the first
cohort and according to the 2014 NIH consensus criteria in the
second cohort.16 The 2014 NIH scoring form collected information
regarding the attribution of joint/fascia abnormalities; 8 patients (2%)
and 93 visits (7%) in the second cohort had joint/fascia abnormalities
entirely explained by causes other than GVHD and were excluded
from analyses. Among the 488 patients in the first cohort, 209 (43%)
had joint/fascia involvement in at least 1 visit and thus comprised
a training cohort. Among the 357 patients in the second cohort, 191
(54%) had joint/fascia involvement in at least 1 visit and thus
comprised a replication cohort. At enrollment and every 6 months
thereafter, clinicians and patients reported standardized information
about chronic GVHD organ involvement and manifestations. Incident
cases had an additional assessment at 3 months after enrollment.
Patients were treated according to institutional practice in compli-
ance with the NIH chronic GVHD consensus guidelines. The study
protocol was approved by the institutional review board of each
participating center, and all participants or their guardians provided
written informed consent in accordancewith theDeclaration of Helsinki.
Statistical analysis
Joint/fascia involvement was defined as NIH joint/fascia score$1 at
any study visit. At follow-up visits every 3 to 6 months, as an anchor
of response, both clinician and patient separately rated their
perception of change in joint/fascia manifestations on the following
8-point scale: 1, completely gone; 2, very much better; 3, moderately
better; 4, a little better; 5, about the same; 6, a little worse; 7,
moderately worse; and 8, very much worse. Clinicians and patients
were asked about symptom changes in joints compared with
previous visits in the training cohort and compared with enrollment
visits in the replication cohort. Categorical perceptions of clinicians
and patients were defined by the collapsed 8-point scale into the
following categories: improved (1-3), stable (4-6), or worse (7-8).
Longitudinal change scores for scales were calculated by subtracting
previous visit values (training cohort) or enrollment values (replication
cohort) from current values. Successive visits in the training cohort
and enrollment and follow-up visits in the replication cohort were
analyzed in pairs. The analysis was limited to paired visits where at
least 1 NIH joint/fascia score was .0. To account for within-patient
correlation, linear mixed models with random patient effect were used
to evaluate correlations between response categories and clinician-
or patient-perceived 0-to-8 changes in joint status. Linear mixed
models were chosen because the models were not appreciably
affected by missing data.17,18 Analysis was stratified by case type
(incident [enrollment ,3 months after chronic GVHD diagnosis]
or prevalent [enrollment$3 months after chronic GVHD diagnosis
but within 3 years after transplantation]). Clinically meaningful
changes were defined by the distribution method (half a standard
deviation) and anchor-based methods (changes in the measures
Total P-ROMIndividual P-ROM (2014 NIH)


































Figure 1. Response according to the P-ROM
score at 455 paired visits in the training cohort.
Table 2. Overall assessment for 56 paired visits with divergent
assessments between individual joints
Measure Improved, n (%) Stable, n (%) Worse, n (%)
Clinician perception 15 (28) 38 (68) 3 (5)
Patient perception* 14 (33) 24 (57) 4 (10)
Total P-ROM score 5 (9) 49 (88) 2 (4)
Individual P-ROM score (2014 NIH) 0 (0) 0 (0) 56 (100)
*Patient perception missing in 14 paired visits.
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that correlated with patient- or clinician-reported changes in joint/
fascia involvement).10 Statistical analyses were performed using
STATA (version 12.1; StataCorp, College Station, TX). Two-sided
P , .05 was considered statistically significant.
Results
Patient characteristics
Patient characteristics at enrollment are listed in Table 1. The training
and replication cohorts were balanced regarding sex, race, stem cell
source, conditioning intensity, and organ involvement, except that
skin, joint/fascia, lung, and genital manifestations were more
frequent in the replication cohort. There were more incident cases
in the training cohort compared with the replication cohort. NIH
global severity scores were more severe in the replication cohort.
P-ROM scores were slightly lower in the replication cohort. The
values for half a standard deviation in individual P-ROM scores
ranged from 0.29 to 0.70, confirming that a 1-point change in
individual P-ROM score is clinically meaningful according to the
distribution method. One half of a standard deviation in total
P-ROM score was 1.17 in the training cohort and 1.49 in the
replication cohort, indicating that a 2-point change in total P-ROM
score is clinically meaningful.
Divergent response in individual P-ROM scores
Response based on P-ROM score is shown in Figure 1 for 455
paired visits in the training cohort where joint/fascia manifestations
were documented in the previous or current visit. Worse individual
P-ROM scores (ie, worse by $1 point) occurred in 15% to 21% of
paired visits. When individual P-ROM scores were used for
calculating overall response, as recommended by the 2014 NIH
response criteria, 26% showed improvement (ie, improvement by
$1 point in any joint without worsening in any other joints), 32%
showed stability, and 43% showed worsening, because wors-
ening in any joint (ie, worse by $1 point) is considered overall
worsening, even in divergent cases where other joints are
improved. Such divergent responses occurred in 56 (12%) of
the 455 paired visits. Notably, few of these divergent cases were
perceived as worse by clinicians or patients (5% and 10%,
respectively; Table 2), and most of these cases were perceived
as stable (68% and 57%, respectively; Table 2). According to
total P-ROM score, most of these cases were classified as stable
(Table 2). These results support the use of total P-ROM score for
assessing response.
Clinician and patient perceptions in cases with
a change from 0 to 1 in NIH joint/fascia score without
worsening in total P-ROM score
Clinician and patient perceptions are summarized in Table 3 for 63
(14%) of the 455 paired visits in the training cohort where NIH
joint/fascia score changed from 0 to 1 and total P-ROM score did
not worsen. Very few clinicians and patients perceived worsening
in those cases (3% and 8%, respectively), indicating that a change
from 0 to 1 in NIH joint/fascia score should not be considered as
worsening, as recommended for other sites in the 2014 NIH
algorithm.
Divergent response between NIH joint/fascia score
and total P-ROM score
Agreement in response in the training cohort between NIH joint/
fascia score and total P-ROM score is summarized in Table 4. Only
13 (2.9%) of the 455 paired visits in the training cohort showed
divergent response between NIH joint/fascia score and total
P-ROM score; the response category was improved by total
P-ROM score but worse by NIH joint/fascia score in 4 paired visits,
and the response category was worse by total P-ROM score but
improved by NIH joint/fascia score in 9 paired visits. These 13
paired visits were perceived most frequently as stable (54%) or
improved (38%) by clinicians but as stable (44%) or worse (33%)
by patients. These results indicate that overall response cannot be
determined in these rare divergent cases.
Development of a refined response algorithm for
joint/fascia GVHD and assessment of its performance
in a replication cohort
On the basis of the analysis of results in the training cohort,
we developed an evidence-based, refined response algorithm for
joint/fascia GVHD (Figure 2). The refined algorithm incorporates
changes in both NIH joint/fascia score and total P-ROM score for
definition of response. At least 1-point changes, except for a change
from 0 to 1 in NIH joint/fascia score and at least 2-point changes in
total P-ROM score, are defined as clinically meaningful changes.
Divergent changes between NIH joint/fascia score and total
P-ROM score are considered uninterpretable.
The proportion of paired visits with worsening of joint/fascia
GVHD was ;50% according to the 2014 NIH algorithm, but
this decreased to ,20% according to the refined algorithm in
both training and replication cohorts (Figure 3). Response was
uninterpretable when divergent changes between NIH joint/fascia
score and total P-ROM score occurred in a few paired visits.
Agreement in response between the 2014 NIH algorithm and the
refined algorithm is summarized in Table 5. Reclassification
occurred in 184 (40%) of 455 paired visits in the training cohort
and in 152 (35%) of 429 paired visits in the replication cohort. As
expected, the refined algorithm reclassified some improved cases
as stable and many worsened cases as improved or stable. This
observation held true in the independent replication cohort.
Table 3. Overall assessment for 63 paired visits with change in NIH
joint/fascia score from 0 to 1 without worsening in total
P-ROM score
Measure Improved, n (%) Stable, n (%) Worse, n (%)
Clinician perception 32 (51) 29 (46) 2 (3)
Patient perception* 18 (34) 31 (58) 4 (8)
*Patient perception missing in 10 paired visits.




Improve Stable Worse (except for 0-1)
Improved 32 27 4*
Stable 96 199 17
Worse 9* 53 18
*Divergent response.
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Estimated differences in clinician- and patient-perceived 0-to-8
changes in joint/fascia manifestations were compared between the
2014 NIH algorithm and the refined algorithm (Figure 4). Separate
analysis in incident and prevalent cases showed similar results in
both case types. The major problem with the 2014 algorithm was
classification of cases perceived as stable by clinicians as worsening.
The refined algorithm corrected most of these misclassifications,
resulting in the worse vs stable groups moving appropriately to
the right (indicating worsening) for clinician perception. Patient
perception in the training cohort did not change appreciably
between the worse vs stable groups with either algorithm, and the
refined algorithm showed worsened patient perception in prevalent
cases of the replication cohort. Overall, changes in perception by
both clinicians and patients with the refined algorithm were larger
than those with the 2014 NIH algorithm, indicating better concor-
dance with reported clinically meaningful perceptions.
Discussion
This study solves many contradictions and problems related to the
2014 NIH response algorithm for assessment of joint/fascia
changes that was recommended based on expert opinion.10 First,
we confirmed that a 1-point change in individual P-ROM score and
2-point change in total P-ROM score are clinically meaningful based
on prospectively collected multicenter data of patients with chronic
GVHD. Second, a change from 0 to 1 in NIH joint/fascia score
should not be considered worse, because only a few clinicians and
patients perceived worsening of GVHD in joints and fascia in real-
world experience. This rule is identical to the approach recom-
mended for other sites in the 2014 NIH response criteria.10 Third,
total P-ROM score offers a better approach than individual P-ROM
scores for categorizing divergent responses in individual joints,
which occurred in .10% of paired visits. Lastly, our real-world
evidence data support defining overall response as uninterpretable
when rare divergent responses remain between NIH joint/fascia
score and total P-ROM score despite application of the refined
algorithm.
The proportion of paired visits with worse joint/fascia GVHD was
;30% lower in both the training and replication cohorts according
to the refined algorithm compared with the 2014 NIH algorithm.
Reclassification of response categories occurred in both directions,
with some improved cases changed to stable and many worsened
cases reclassified as stable or even improved. The refined algorithm
led to overall better delineation of clinician- or patient-perceived
Refined NIH Response Algorithm for Joint/fascia GVHD
Based on 2 subscores: NIH joint/fascia score & total P-ROM score
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Figure 2. Refined response algorithm for chronic












































Figure 3. Response categories according to 2014 NIH algorithm and refined
algorithm for chronic GVHD in joints and fascia.
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changes compared with the 2014 NIH algorithm, as shown in
Figure 4. The point estimates for many of the change categories
are overall stepwise farther away from 0 in the minus (improved)
direction and plus (worsening) direction, with tight confidence
intervals. The 2014 NIH algorithm performed poorly in capturing
differences between the worse and stable groups in either the
training or replication cohort. In contrast, the refined algorithm
captured differences between the worse and stable groups in
clinician perception in both cohorts, as well as in patient
perception in the replication cohort but not in the training
cohort.
The current NIH response criteria tools for assessing joint/fascia
GVHD have several other issues that will require future refinement
and investigation. First, ROM is sometimes not symmetrical, and the
NIH criteria do not state whether the better or worse joint should be
scored. One solution might be to score left and right joints
separately, but this modification would need validation. Second,
patient joint positioning for P-ROM assessment should be
standardized, and images should be collected for archived
documentation when response assessment is essential, as for
clinical trials. Third, P-ROM does not capture fascial involvement in
the abdomen or chest wall, which can significantly affect physical
functioning. Lung function values such as FEV1 and vital capacity
percentages may reflect mobility of the chest wall, although formal
validation has not been performed. Fourth, data in the pediatric
population are limited. Finally, guidance is required when edema
that could mimic early fasciitis or worsening sclerosis is present.
Gentle pressure on the area can sometimes expel edema, allowing
more accurate assessment of skin thickening from fibrosis. More
refined tools and better technologies are required to solve these
challenges.
In conclusion, this study provides a substantially improved algo-
rithm for assessing therapeutic response in chronic GVHD involv-
ing joints and fascia based on empirical data from 2 independent
prospective multicenter cohorts. This evidence-based refined
algorithm for joint/fascia GVHD is appropriate for use in clinical
trials. Because both the 2014 and the refined response algorithms




Improved Stable Worse Uninterpretable
Training cohort
Improved 132 26* 0 0
Stable 0 51 0 0
Worse 23* 122* 88 13*†
Replication cohort
Improved 137 37* 0 0
Stable 0 69 0 0
Worse 23* 82* 71 10*†
*Reclassification occurred in 184 paired visits (40%) in the training cohort and in 152
paired visits (35%) in the replication cohort.
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Figure 4. Estimated differences in clinician- and patient-perceived changes in joint/fascia manifestations according to response categories defined by 2014
NIH algorithm and refined algorithm. Estimated differences in clinician- or patient-perceived 0-to-8 changes were calculated using linear mixed models with random patient
effect in the respective comparisons. For example, estimated difference among improved patients according to the 2014 NIH algorithm compared with stable patients accord-
ing to the same algorithm is shown in top left. Analysis was stratified by case type (incident [red; enrollment ,3 months after chronic GVHD diagnosis] or prevalent [blue;
enrollment $3 months after chronic GVHD diagnosis but within 3 years after transplantation]). Squares and diamonds indicate point estimates, and bars indicate 95% confi-
dence intervals.
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use the same input data, clinical trials in progress will be able to
evaluate outcomes according to both algorithms.
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